Information Provided By: 
Fly News Breaks for August 17, 2017
IMMU
Aug 17, 2017 | 06:57 EDT
Jefferies analyst Matthew Andrews says that even though shares of Immunomedics are up 113% year-to-date, he still likes the setup into the end of 2017 and into Q1 of 2018. The company remains his top small-cap pick with a Buy rating and $11 price target. The analyst sees a potential new CEO and final triple-negative breast cancer data in December as potential catalysts.
News For IMMU From the Last 2 Days
There are no results for your query IMMU
